End-Payors Ink $30M Novartis Exforge Deal
By Nadia Dreid · February 23, 2023, 10:47 PM EST
Novartis has reached another deal to shake off claims that it hatched an illegal deal with Par Pharmaceuticals to delay the release of a generic version of the blood pressure drug...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login